Molecular Formula | C21H24ClN2NaO4S |
Molar Mass | 458.93 |
Melting Point | 1800C |
Solubility | DMSO: ≥20mg/mL |
Appearance | solid |
Color | white to tan |
Merck | 14,9420 |
Storage Condition | Desiccate at RT |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 2 months. |
In vivo study | In unstressed rats, Tianeptine treatment prevents CMS-induced increases in corticotropin-releasing factor (CRF)mRNA levels in dBNST, and reduce the mRNA level of corticotropin releasing factor (CRF) in dBNST. Tianeptine treatment significantly reduced CRF mRNA levels in ventral BNST and CEA in stress-avoidance controls as well as in CMS-exposed rats. In the basolateral nucleus (BLA) of the amygdala of anesthetized rats, Tianeptine blocked the stress-induced enhancement of PB in the CA1 region without affecting the stress-induced enhancement of LTP. In the amygdala, hippocampus and LTP of anesthetized rats, Tianeptine administered enhanced PB enhancement under non-stress conditions. In rats, Tianeptine attenuates the behavioral signs of peripheral-induced, but not central, LPS, or IL-1β-induced, morbid behavior. In rats, Tianeptine causes the normalized ratio of the amplitude ratio of the NMDA receptor to AMPA/kainate receptor-mediated currents and prevents the attenuation of stress-induced NMDA-EPSCS inactivation. Both in control and stressed animals, in the rat temporal cortex and hippocampal dentate gyrus, Tianeptine significantly reduced apoptosis, but had no effect on the Horn of Africa Ammons. Only in the nucleus accumbens, Tianeptine(2.5 mg/kg, I. P.) increased extracellular dopamine. In both nucleus accumbens and striatum, Tianeptine significantly increased the extracellular concentrations of hydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). |
WGK Germany | 3 |